QIAstat-Dx Cartridge
MAIN port
Any liquid sample type up to 1.5 mL
INNOVATIVE solution
All reagents on-board to provide comprehensive results
in about an hour
Discover the QIAstat-Dx Analyzer
The next generation of multiplex syndromic testing
Explore features
QIAstat-Dx Cartridge
A fully-contained test that can detect 20 or more targets*. Simply add the sample and let the QIAstat-Dx system do the rest.
*depending on respiratory panel type
Available assays:
QIAstat-Dx Respiratory Panel
True Sample to Insight solution for patients with suspected upper respiratory infections
- Detects 20 viral and bacterial targets in about an hour
- Wet and dry reagents on-board
- No precision pipetting required
- Room temperature storage
The QIAstat-Dx Analyzer and the QIAstat-Dx Respiratory Panel are intended for in vitro diagnostic use.
QIAstat-Dx Respiratory SARS-CoV-2 Panel (Emergency Use Authorization)
This expanded version of our multiplex respiratory cartridge detects and differentiates 21 viral and bacterial respiratory targets, including SARS-CoV-2.
The QIAstat-Dx Analyzer and the QIAstat-Dx Respiratory Panel are intended for in vitro diagnostic use.
QIAstat-Dx Respiratory SARS-CoV-2 Panel is intended for in vitro diagnostic use under Emergency Use Authorization Only. Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high complexity and moderate complexity tests.
The QIAstat-Dx Respiratory SARS-CoV-2 Panel has not been FDA cleared or approved;
The QIAstat-Dx Respiratory SARS-CoV-2 Panel has been authorized by FDA under an EUA for use by authorized laboratories;
The QIAstat-Dx Respiratory SARS-CoV-2 Panel has been authorized only for the detection and differentiation of nucleic acid of SARS-CoV-2 from multiple respiratory viral and bacterial organisms;
The QIAstat-Dx Respiratory SARS-CoV-2 Panel is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
